
Early Bird Prime for November 22, 2026
Humana $HUM ( ▲ 2.63% ), the name that once sent shivers down investors' spines, now seems to be the talk of the town for all the right reasons. Humana's stock is up 47.46% this year.

Picture this: it's March 2026, and Humana's stock is lounging at a 52-week low of $163.11. Fast forward a few months, and the story changes. Improved Star Ratings, stronger revenue, and optimistic guidance have investors buzzing.
A few days ago, an analyst from TD Cowen jumped on the bandwagon, upgrading Humana to a 'Buy' from a 'Hold'. The analyst is optimistic about potential profitability and earnings growth,
But let's take a step back. What if this recovery is like waiting for a bus that never arrives? The apparent bargain could vanish fast.
Humana has made it clear that margin recovery is its top priority for 2027 Medicare plans. TD Cowen's bullish assessment suggests that competitors are also playing nice, reducing the risk of Humana's pricing actions backfiring. But let's not forget, this is all based on assumptions about customer and competitor behavior.
Should you buy or avoid Humana's stock right now in 2026? Here’s the answer…
Subscribe to Early Bird Prime to read the rest.
Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.
UpgradeAlready a subscriber? Sign in
A subscription gets you:
- Expert analysis on the best stocks.
- Stock price predictions based on machine learning.
- Investing picks and recommendations.
- Advertisement-free.
